Every 10-Q that Celldex Therapeutics Inc (CLDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLDX filings page.
Celldex Therapeutics reported a larger loss as it scales late-stage development of its lead antibody barzolvolimab. For the quarter ended June 30, 2026, net loss was $73.5 million (basic and diluted loss per share $0.94), versus $56.6 million a year earlier, driven by higher research and development spending. R&D expense rose to $67.5 million in the quarter and $140.5 million year‑to‑date, including $117.1 million devoted to the barzolvolimab/anti‑KIT program.
Liquidity strengthened after an April 2026 underwritten equity offering of 11.9 million shares that generated $323.8 million in net proceeds. At June 30, 2026, cash, cash equivalents and marketable securities totaled $717.6 million, with stockholders’ equity of $714.6 million. Management believes this balance will fund planned operations for at least twelve months from issuance of the financial statements.
Clinically, barzolvolimab is in global Phase 3 trials for chronic spontaneous urticaria with topline data expected in September/October 2026, and in Phase 3 for chronic inducible urticarias. A Phase 2 atopic dermatitis study is fully enrolled. After a Phase 2 miss, prurigo nodularis development is being discontinued. Bispecific candidate CDX‑622 completed a Phase 1 trial in healthy volunteers with supportive pharmacodynamic data and entered a proof‑of‑mechanism study in asthma.
Celldex Therapeutics reported a larger quarterly loss as it accelerates late-stage development of its lead antibody barzolvolimab. For the three months ended March 31, 2026, revenue was $15 thousand while research and development expenses rose to $73.0 million, driving a net loss of $78.7 million.
Cash, cash equivalents and marketable securities totaled $451.5 million at March 31, 2026, and an April 2026 underwritten offering added about $323.9 million of net proceeds. Management believes these resources can fund current planned operations through 2028 while Phase 3 urticaria trials and Phase 2 programs in prurigo nodularis and atopic dermatitis progress.
Celldex Therapeutics (CLDX) filed its Q3 2025 10-Q, reporting no revenue for the quarter and higher operating spend as clinical programs advanced. For the three months ended September 30, 2025, operating expenses were $73.6 million and the company recorded a net loss of $67.0 million (vs. $42.1 million a year ago). For the nine months, operating expenses were $201.6 million with a net loss of $177.4 million.
Liquidity remains strong: as of September 30, 2025, cash, cash equivalents and marketable securities totaled $583.2 million. Net cash used in operating activities was $147.0 million for the nine months. Management states these resources are expected to fund operations for at least the next twelve months from issuance. R&D spend is led by the barzolvolimab (anti‑KIT) program, which accounted for $133.97 million of R&D in the nine-month period; CDX‑622 and other programs accounted for the balance. An at‑the‑market facility with $300.0 million registered capacity remained unsold at quarter end. Common shares outstanding were 66,446,846 at September 30, 2025.